{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:25Z","timestamp":1791903325570,"version":"4.3.4"},"reference-count":9,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"DOI":"10.1182\/bloodadvances.2026021747","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:31:15Z","timestamp":1790782275000},"page":"6683-6684","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["CC-486 plus venetoclax: another step toward oral AML therapy"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1089-9907","authenticated-orcid":false,"given":"Kimberly","family":"Seymour","sequence":"first","affiliation":[{"name":"Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"issue":"19","key":"2026101310435081600_bib1","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1182\/bloodadvances.2026020179","article-title":"A Phase 1\/1b Study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia","volume":"10","author":"Amaya","year":"2026","journal-title":"Blood Adv"},{"issue":"10","key":"2026101310435081600_bib2","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biologic correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"5","key":"2026101310435081600_bib3","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"issue":"7","key":"2026101310435081600_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2026101310435081600_bib5","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(24)00033-4","article-title":"Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study","volume":"11","author":"Bazinet","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026101310435081600_bib6","unstructured":"U.S. Food and Drug Administration\n          . FDA approves oral decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia. Updated 13 May 2026. Accessed 12 August 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-oral-combination-decitabine-and-cedazuridine-tablets-venetoclax-newly-diagnosed-acute."},{"issue":"26","key":"2026101310435081600_bib7","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026101310435081600_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2025-491","article-title":"A phase 2 dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"146","author":"Garcia-Manero","year":"2025","journal-title":"Blood"},{"key":"2026101310435081600_bib9","unstructured":"A multi-phase study of ASTX030 (azacitidine and cedazuridine) in myeloid neoplasm alone or in combination with venetoclax in AML (AZTOUND study). ClinicalTrials.gov identifier: NCT04256317. Updated 30 April 2026. Accessed 12 August 2026. https:\/\/clinicaltrials.gov\/study\/NCT04256317."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6683\/2592921\/blooda_adv-2026-021747-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6683\/2592921\/blooda_adv-2026-021747-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:03Z","timestamp":1791902643000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6683\/571303\/CC-486-plus-venetoclax-another-step-toward-oral"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":9,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026021747","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,26]]}}}